ALFA Filings
Every announcement, straight from the exchange
Every OneSource Specialty Pharma earnings call announcement on NSE and BSE, newest first, each with its own page.
Time
5 announcements with these filters
Onesource Specialty Pharma delivered its third consecutive growth quarter, driven by new sterile cartridge capacity.
OneSource reported strong Q1 FY27 results with Revenue of INR 4,490M (up 37% YoY) and EBITDA of INR 1,233M (up 39% YoY), driven by semaglutide commercialization and biologics expansion.
Management is aggressively optimistic, leveraging the GLP-1 (Semaglutide) boom to mask temporary supply disruptions. Strategic shift toward CDMO for Softgel and Biologics aims to diversify beyond traditional captive manufacturing.
Q4 FY26 marked a strong recovery with 47% sequential revenue growth to US$48M, driven by Semaglutide launches and drug-device combinations.
Onesource Q4 FY26 shows strong sequential recovery driven by semaglutide drug-device combination launches, although annual profits were dragged down by prior delays and exceptional items.